what are glp 1's GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes What Should I Expect During

Participants on Zepbound also experienced substantial weight loss -- averaging 18% to 20% of their body weight (approximately 45 to 50 pounds) over the course of a year -- compared to 1.6% to 2.3% for those on placebo

Assets Download Contact Jen Treadwell [email protected] 1

Clinical trials have shown that WEGOVY leads to greater weight loss compared to other treatments, including Eli Lillys ZEPBOUND , reinforcing its position as a top obesity treatment

While some of the trials reported a decrease in appetite as a side effect, like the ADJUNCT trials (5358, 60), it should be noted that this is one of the main mechanisms of action of these drugs to achieve weight loss

SymptoGuard does not have any affiliation with and is not endorsed by these brands or their parent companies

Another issue involves patient expectations